Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05058638 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Aquamin® in Mitigating Halitosis
A Phase 2 study of Healthy and Halitosis, sponsored by University of Michigan.
- Active
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05058638: Active Phase 2 study of Healthy and Halitosis, sponsored by University of Michigan.
NCT05058638 is a Phase 2 study of Healthy and Halitosis that is active but no longer recruiting, run by University of Michigan. The registered enrollment target is 15 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05058638, a Phase 2 study of Healthy and Halitosis, is active but no longer recruiting, sponsored by University of Michigan.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess whether Aquamin®, a multi-mineral natural product from red marine algae, can help reduce halitosis when taken for 90 days.
Primary Outcome
Following the intervention, participants will answer questions regarding if their bad breath has improved over the course of the study compared to the starting point. The scores will be from 0 (no issue) - 5 (worst possible issue) for each question.
Interventions
- DRUG Aquamin
Study Locations (1)
Michigan
- University of Michigan School of Dentistry - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-08-15 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT05058638 still lists
NCT05058638 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Aquamin is the first listed.
NCT05058638 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05058638 about?
NCT05058638 is a clinical study titled "Effectiveness of Aquamin® in Mitigating Halitosis". The purpose of this study is to assess whether Aquamin®, a multi-mineral natural product from red marine algae, can help reduce halitosis when taken for 90 days.
What is the current status of trial NCT05058638?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2022-08-15. Estimated completion is 2026-12.
What conditions does trial NCT05058638 study?
This clinical trial studies the following conditions: Healthy, Halitosis.
What interventions are being tested in trial NCT05058638?
The interventions under investigation include: Aquamin (DRUG).
Who is sponsoring clinical trial NCT05058638?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05058638 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05058638's enrollment target sits among peer trials
15 955th of 1090 higher than 118 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Effects of an Antioxidant Supplement on Blood Vessel Health
RECRUITING · Phase 2
-
Atenolol for the Prevention of Osteoporosis (APO)
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers
COMPLETED · Phase 2
-
Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI